title: Tumefactive demyelination presenting during bevacizumab treatment.
abstract: We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.
authors.affiliation: Department of Neurology, North Bristol, NHS Trust Bristol, UK School of Clinical Sciences, University of Bristol, Bristol, UK.
authors.forename: Claire M
authors.initials: CM
authors.lastname: Rice
authors.affiliation: Department of Neurology, North Bristol, NHS Trust Bristol, UK.
authors.forename: David
authors.initials: D
authors.lastname: Rossiter
authors.affiliation: Department of Neurology, North Bristol, NHS Trust Bristol, UK.
authors.forename: Janev
authors.initials: J
authors.lastname: Fehmi
authors.affiliation: Department of Neurology, North Bristol, NHS Trust Bristol, UK.
authors.forename: James C
authors.initials: JC
authors.lastname: Stevens
authors.affiliation: Department of Neuroradiology, North Bristol, NHS Trust Bristol, UK.
authors.forename: Shelley A
authors.initials: SA
authors.lastname: Renowden
authors.affiliation: School of Clinical Sciences, University of Bristol, Bristol, UK Department of Neuropathology, North Bristol, NHS Trust Bristol, UK.
authors.forename: Nicki
authors.initials: N
authors.lastname: Cohen
authors.affiliation: Bristol Eye Hospital, Lower Maudlin Street, Bristol, UK.
authors.forename: Clare
authors.initials: C
authors.lastname: Bailey
authors.affiliation: Department of Neurology, North Bristol, NHS Trust Bristol, UK School of Clinical Sciences, University of Bristol, Bristol, UK.
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Scolding
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D020256:Choroidal Neovascularization / Q000473:pathology; D003711:Demyelinating Diseases / Q000134:cerebrospinal fluid / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab